326 related articles for article (PubMed ID: 34276659)
1. Complement Anaphylatoxins and Inflammatory Cytokines as Prognostic Markers for COVID-19 Severity and In-Hospital Mortality.
Alosaimi B; Mubarak A; Hamed ME; Almutairi AZ; Alrashed AA; AlJuryyan A; Enani M; Alenzi FQ; Alturaiki W
Front Immunol; 2021; 12():668725. PubMed ID: 34276659
[TBL] [Abstract][Full Text] [Related]
2. Elevated Expression Levels of Lung Complement Anaphylatoxin, Neutrophil Chemoattractant Chemokine IL-8, and RANTES in MERS-CoV-Infected Patients: Predictive Biomarkers for Disease Severity and Mortality.
Hamed ME; Naeem A; Alkadi H; Alamri AA; AlYami AS; AlJuryyan A; Alturaiki W; Enani M; Al-Shouli ST; Assiri AM; Alosaimi B
J Clin Immunol; 2021 Oct; 41(7):1607-1620. PubMed ID: 34232441
[TBL] [Abstract][Full Text] [Related]
3. Cytokine Profiles Associated With Worse Prognosis in a Hospitalized Peruvian COVID-19 Cohort.
Pons MJ; Ymaña B; Mayanga-Herrera A; Sáenz Y; Alvarez-Erviti L; Tapia-Rojas S; Gamarra R; Blanco AB; Moncunill G; Ugarte-Gil MF
Front Immunol; 2021; 12():700921. PubMed ID: 34539631
[TBL] [Abstract][Full Text] [Related]
4. Serum IL-6: A potential biomarker of mortality among SARS-CoV-2 infected patients in Mexico.
Avila-Nava A; Cortes-Telles A; Torres-Erazo D; López-Romero S; Chim Aké R; Gutiérrez Solis AL
Cytokine; 2021 Jul; 143():155543. PubMed ID: 33896708
[TBL] [Abstract][Full Text] [Related]
5. Longitudinal COVID-19 profiling associates IL-1RA and IL-10 with disease severity and RANTES with mild disease.
Zhao Y; Qin L; Zhang P; Li K; Liang L; Sun J; Xu B; Dai Y; Li X; Zhang C; Peng Y; Feng Y; Li A; Hu Z; Xiang H; Ogg G; Ho LP; McMichael A; Jin R; Knight JC; Dong T; Zhang Y
JCI Insight; 2020 Jul; 5(13):. PubMed ID: 32501293
[TBL] [Abstract][Full Text] [Related]
6. Effect of artificial liver blood purification treatment on the survival of critical ill COVID-19 patients.
Dai X; Zhang Y; Yu L; Jiang YA; Chen L; Chen Y; Li M; Gao C; Shang J; Xiang S; Li Y; Li J; Zhou C; Zhou X; Chen N; Liu Y; Liu J; Zhang Y; Chen X; Zhu D; Gao H; Tang L; Zhu M; Li L
Artif Organs; 2021 Jul; 45(7):762-769. PubMed ID: 33326621
[TBL] [Abstract][Full Text] [Related]
7. Association between inflammatory cytokines/chemokines, clinical laboratory parameters, disease severity and in-hospital mortality in critical and mild COVID-19 patients without comorbidities or immune-mediated diseases.
Hamza M; Alhujaily M; Alosaimi B; El Bakkouri K; AlDughaim MS; Alonazi M; Alanazi MA; Abbass B; Alshehri A; Al-Shouli ST; Alturaiki W; Awadalla M
J Immunoassay Immunochem; 2023 Jan; 44(1):13-30. PubMed ID: 35915975
[TBL] [Abstract][Full Text] [Related]
8. Increased Serum Levels of Soluble TNF-α Receptor Is Associated With ICU Mortality in COVID-19 Patients.
Mortaz E; Tabarsi P; Jamaati H; Dalil Roofchayee N; Dezfuli NK; Hashemian SM; Moniri A; Marjani M; Malekmohammad M; Mansouri D; Varahram M; Folkerts G; Adcock IM
Front Immunol; 2021; 12():592727. PubMed ID: 33968010
[TBL] [Abstract][Full Text] [Related]
9. Complement C5a and Clinical Markers as Predictors of COVID-19 Disease Severity and Mortality in a Multi-Ethnic Population.
Cyprian FS; Suleman M; Abdelhafez I; Doudin A; Masud Danjuma M; Mir FA; Parray A; Yousaf Z; Siddiqui MYA; Abdelmajid A; Mulhim M; Al-Shokri S; Abukhattab M; Shaheen R; Elkord E; Al-Khal AL; Elzouki AN; Girardi G
Front Immunol; 2021; 12():707159. PubMed ID: 34966381
[TBL] [Abstract][Full Text] [Related]
10. Cytokine Profiles Before and After Immune Modulation in Hospitalized Patients with COVID-19.
Azmy V; Kaman K; Tang D; Zhao H; Dela Cruz C; Topal JE; Malinis M; Price CC
J Clin Immunol; 2021 May; 41(4):738-747. PubMed ID: 33459964
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of interleukin-18 and its association with other inflammatory markers and disease severity in COVID-19.
Satış H; Özger HS; Aysert Yıldız P; Hızel K; Gulbahar Ö; Erbaş G; Aygencel G; Guzel Tunccan O; Öztürk MA; Dizbay M; Tufan A
Cytokine; 2021 Jan; 137():155302. PubMed ID: 33002740
[TBL] [Abstract][Full Text] [Related]
12. Cytokine profiling in Iranian patients with COVID-19; association with clinical severity.
Taghiloo S; Soltanshahi M; Aliyali M; Abedi S; Mehravaran H; Ajami A; Asgarian-Omran H
Iran J Immunol; 2021 Mar; 18(1):54-64. PubMed ID: 33787514
[TBL] [Abstract][Full Text] [Related]
13. Galectin-9, a Player in Cytokine Release Syndrome and a Surrogate Diagnostic Biomarker in SARS-CoV-2 Infection.
Bozorgmehr N; Mashhouri S; Perez Rosero E; Xu L; Shahbaz S; Sligl W; Osman M; Kutsogiannis DJ; MacIntyre E; O'Neil CR; Elahi S
mBio; 2021 May; 12(3):. PubMed ID: 33947753
[TBL] [Abstract][Full Text] [Related]
14. Mini-Factor H Modulates Complement-Dependent IL-6 and IL-10 Release in an Immune Cell Culture (PBMC) Model: Potential Benefits Against Cytokine Storm.
Kozma GT; Mészáros T; Bakos T; Hennies M; Bencze D; Uzonyi B; Győrffy B; Cedrone E; Dobrovolskaia MA; Józsi M; Szebeni J
Front Immunol; 2021; 12():642860. PubMed ID: 33995361
[TBL] [Abstract][Full Text] [Related]
15. Viral loads, lymphocyte subsets and cytokines in asymptomatic, mildly and critical symptomatic patients with SARS-CoV-2 infection: a retrospective study.
Yin SW; Zhou Z; Wang JL; Deng YF; Jing H; Qiu Y
Virol J; 2021 Jun; 18(1):126. PubMed ID: 34118952
[TBL] [Abstract][Full Text] [Related]
16. Potent SARS-CoV-2-Specific T Cell Immunity and Low Anaphylatoxin Levels Correlate With Mild Disease Progression in COVID-19 Patients.
Lafon E; Diem G; Witting C; Zaderer V; Bellmann-Weiler RM; Reindl M; Bauer A; Griesmacher A; Fux V; Hoermann G; Miller C; Zabernigg A; Wöll E; Wilflingseder D; Lass-Flörl C; Posch W
Front Immunol; 2021; 12():684014. PubMed ID: 34194438
[TBL] [Abstract][Full Text] [Related]
17. Elevated Cytokine Levels in Plasma of Patients with SARS-CoV-2 Do Not Contribute to Pulmonary Microvascular Endothelial Permeability.
Kovacs-Kasa A; Zaied AA; Leanhart S; Koseoglu M; Sridhar S; Lucas R; Fulton DJ; Vazquez JA; Annex BH
Microbiol Spectr; 2022 Feb; 10(1):e0167121. PubMed ID: 35171047
[TBL] [Abstract][Full Text] [Related]
18. The Role of Inflammatory Cytokines (Interleukin-1 and Interleukin-6) as a Potential Biomarker in the Different Stages of COVID-19 (Mild, Severe, and Critical).
Ghofrani Nezhad M; Jami G; Kooshkaki O; Chamani S; Naghizadeh A
J Interferon Cytokine Res; 2023 Apr; 43(4):147-163. PubMed ID: 37062817
[TBL] [Abstract][Full Text] [Related]
19. Circulating Levels of Interleukin-6 and Interleukin-10, But Not Tumor Necrosis Factor-Alpha, as Potential Biomarkers of Severity and Mortality for COVID-19: Systematic Review with Meta-analysis.
Udomsinprasert W; Jittikoon J; Sangroongruangsri S; Chaikledkaew U
J Clin Immunol; 2021 Jan; 41(1):11-22. PubMed ID: 33128665
[TBL] [Abstract][Full Text] [Related]
20. Serum IL-23, IL-10, and TNF-α predict in-hospital mortality in COVID-19 patients.
Smail SW; Babaei E; Amin K; Abdulahad WH
Front Immunol; 2023; 14():1145840. PubMed ID: 37283736
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
